FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study (“BACKBEAT study”), resulting in an estimated more than 24-fold increase in the ...

Revenue for the three months ended June 30, 2025, totaled $10.2 million, an increase of 42%, as compared to $7.2 million for the same period of 2024. This growth was within the Company's guidance of ...

SERB Pharmaceuticals to acquire Y-mAbs in $412.0 million transaction; transaction expected to close by the fourth quarter of 2025, subject to completion of tender offer and other customary conditions ...

Tokyo, Japan and Cambridge, UK, 8 August 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second ...

Les premiers résultats de l’étude confirmatoire de Phase 3 Denali sur NCX 470 sont attendus entre mi-août et mi-septembre 2025 ...

Vistin Pharma ASA will release its second quarter and YTD 2025 results on Friday 15th of August 2025. Vistin Pharma will host a conference call for all shareholders and interested parties at the same ...

Discrets, résistants et difficiles à repérer, les œufs de punaises de lit représentent le point de départ silencieux d’une infestation massive. Leur présence passe souvent inaperçue, mais leur impact ...

Total revenue for the quarter stood at ₹496 Cr, up 77% YoY, led by 113% growth in our CDMO segment and a 38% rise in Discovery revenues, enabled by deeper engagement with global clients.

NCX 470 Denali confirmatory Phase 3 results expected mid-August to mid-September 2025 ...

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, ...

J.P. Morgan, Morgan Stanley and Piper Sandler are acting as joint book-running managers for the offering. Stifel and Canaccord Genuity are acting as co-managers for the offering.

China and European approval for zanidatamab in 2L HER2-positive biliary tract cancer (BTC) expands international patient access Cash resources of $333.4 million as of June 30, 2025 (compared to $324.2 ...